Keeping Current cover art

All Episodes

Keeping Current — 600 episodes

#
Title
1

Addressing Unmet Needs in the Management of Sjögren's Disease: A Spotlight on Emerging Biologic Therapies

2

Challenges and Opportunities in the Diagnostic Pathway for Biliary Atresia

3

Diabetic Macular Edema: Express Q&A on What's New

4

The Science of SGLT1 and SGLT2: Unpacking Dual Inhibition for Heart Failure

5

Liver Fibrosis in Type 2 Diabetes and Obesity: A Case-Based Approach

6

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer

7

New Horizons in Uveitic Macular Edema

8

Metabolic Crossroads: Navigating the Obesity–Liver Disease Axis

9

Beyond the Update in Advanced/Recurrent Endometrial Cancer: How Evidence Is Shaping New Guidelines

10

Beyond PSMA: Preparing Your Practice for the Next Wave of Prostate Cancer Biomarkers

11

Avoiding Common Mistakes in Managing Focal Epilepsy

12

From Prescription to Practice in Respiratory Diseases: Overcoming Barriers to Inhaler Adherence and Compliance

13

The CLL Consultation: Partnering With Patients for Person-Centred Care

14

Immunotherapy for Non-Muscle-Invasive Bladder Cancer: Expert Takeaways From the Latest Updates

15

Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence

16

2025 Winter Conference Update: Novel and Emerging Treatment Strategies for Breast Cancer

17

A Case-Based Journey From Risk to Results

18

HER2-Positive Early Breast Cancer: What the Latest Data Mean for Your Practice

19

Balancing ART and Comorbidities in Aging People Living With HIV

20

The Alarming Carbon Footprint of Respiratory Disease: The Future of Sustainable Inhaler Technology

21

Achieving Brain Health in Epilepsy: What Can Clinicians Do?

22

Patient Case Challenge: How Would You Manage This Patient With MASH?

23

Navigating the Challenges of IgAN Management: Clinical Implications of Emerging B-Cell Therapies

24

Person-Centered Care in EGFR-Mutated Advanced NSCLC: Optimizing Outcomes and Experiences

25

Charting the Course in CLL: A Clinician's Compass for BTK Inhibitor Therapy

26

How Are ADCs Shaping the Future of Early Breast Cancer Care? Latest Insights and Emerging Strategies

27

Pediatric Low-Grade Glioma With BRAF Alterations: Stories, Science, and Strategies

28

Hot Topics from Berlin 2025: What Experts Say About the Future of Metastatic Breast Cancer Care

29

How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer?

30

Staying Ahead of the First Event: Evaluating the Evidence for Early LDL-C Lowering

31

Optimizing Outcomes for Patients With IgAN: Novel B-Cell Targeted Therapies and the Changing Treatment Paradigm

32

Advances in the Pharmacologic Management of Obesity: An Expert Digest of the Latest Data

33

Breaking the Silence: Tackling Liver Fibrosis in MASH: Who to Treat With Novel Therapies

34

Coexisting Comorbidities: Advancing Holistic Care in COPD

35

Novel Biological Approaches for Enhanced Obesity and Diabetes Management – What's Next?

36

Latest Advances in mHSPC: An Update From Berlin 2025

37

Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC

38

Charting the Course for Metastatic Breast Cancer Care: Optimizing First-Line Treatment and Beyond

39

Paving the Way for Success in Integrating Biosimilars Into Multiple Sclerosis Care: Optimizing Communication

40

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC

41

Reshaping Obesity and Diabetes Care With Innovative Multiagonism Concepts

42

The Hidden Battle: Understanding Chronic Inflammation in Aging People Living With HIV and Comorbidities

43

Emerging Therapies for MASH: From Theory to Clinical Practice

44

Interpreting JC Virus Test Results in Multiple Sclerosis Management: Are You Up to Speed?

45

Targeting Diabesity From Multiple Angles: Future Prospects and Imminent Realities

46

Neovascular AMD: Optimizing Disease Control for Your Patients

47

The Hidden Hurdle: Practical Insights on Drug-Drug Interactions in Prostate Cancer Management

48

Managing Diabetic Macular Edema in Clinical Practice

49

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers

50

Thyroid Eye Disease: How to Use Targeted Immunotherapy in Clinical Practice

51

Thyroid Eye Disease: How to Use Targeted Immunotherapy in Clinical Practice

52

Immunopathogenesis of IgAN and the Evolving Treatment Landscape: A Focus on the B-Cell Pathway

53

Targeted Therapies for NSCLC: Where Are We Today?

54

Advances in the Pharmacologic Management of Obesity: Looking Ahead to EASD 2025

55

Squamous Cell Anal Carcinoma: Bridging Current Practice and Future Horizons With Immunotherapy

56

Epilepsy Undertreatment and Overtreatment: How Can We Strike a Balance?

57

Illuminating the Path: New Insights in EGFR-Mutated Advanced NSCLC

58

Antibody-Drug Conjugates in Practice: Contemporary Questions for the Treatment of Metastatic Breast Cancer

59

JC Virus Testing 101: What You Need to Know About JC Virus Testing in Multiple Sclerosis Care

60

The Basis of Success: Recognizing IgAN and Promoting Earlier Diagnosis to Facilitate Treatment Initiation

61

Hormone Receptor-Positive Metastatic Breast Cancer: Novel Endocrine-Based Strategies and Options After Progression

62

Navigating Biomarker Conversations: Empowering Patient Understanding in Gastroesophageal Cancer

63

Long COVID in Context: A Closer Look at Post-Viral Syndrome and Management Approaches

64

Tumor-Like Masses, Abdominal Swelling, Pancreatic Involvement: Making Sense of IgG4-Related Disease, a Multiorgan Fibroinflammatory Condition

65

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach

66

ADA 2025 Highlights: The Weight of Evidence for Emerging Combination Therapies in Obesity and Diabetes Care

67

Advancing Treatment for HER2-Positive Advanced Breast Cancer: Expert Analysis of the Latest Developments

68

Personalized Pathways: Tailoring Care for Patients With Newly Diagnosed Multiple Myeloma

69

Quickfire Updates on Gastric/GEJ Cancers: Latest Data in Perioperative Immunotherapy

70

IgG-Mediated Autoimmune Disorders: A Clinical Update on Novel Therapies Targeting FcRn

71

Breast Cancer Care in 2025: Breakthroughs and Takeaways From Chicago

72

Fresh Perspectives in Thyroid Eye Disease

73

The Evolution of Antibody-Drug Conjugate Therapy for Gastric/GEJ Cancers: Latest Data and Clinical Implications

74

Shared Decision-Making in Epilepsy Today

75

Frontline Frontiers: Revolutionizing Extensive-Stage SCLC Care Through Treatment Innovation

76

Navigating PD-L1 Testing and Patient-Centered Treatment of Gastroesophageal Cancer: A Guide for All Oncology Settings

77

Under the Skin: Revolutionizing Immunotherapy Delivery in Lung Cancer

78

One Team, One Goal: The Key to Better Patient Outcomes in Early Breast Cancer Management

79

Collaborative Management of EGFR-Mutated Advanced NSCLC: A Patient–Care Team Journey

80

New Considerations in Managing Family Planning in Multiple Sclerosis

81

Advancing Precision Oncology: Recent Progress and Future Outlook

82

Advanced HER2-Positive Gastric/GEJ Cancers: Expert Insights on Current and Future Strategies

83

Decoding PD-L1 Scoring: Guiding Immunotherapy for Gastroesophageal Cancers

84

Patient-Centered Paroxysmal Nocturnal Hemoglobinuria Treatment & the Role of Terminal Complement Inhibitors

85

Are We Undertreating Depression in People Living With Epilepsy?

86

Pearls on Retina Biomarkers for Clinical Practice

87

Sharing Expert Minds in Lung Cancer and Lung Neuroendocrine Tumors Delivering Optimal Patient Care

88

COVID-19 Antivirals: Real-World Evidence Review

89

Should We Be Thinking More About Bile Acids in Progressive Cholestatic Liver Diseases?

90

A Year in Review of Antibody-Drug Conjugates for Breast Cancer: Trends, Practice, and Outlook

91

Unveiling the Invisible: The Acute and Chronic Burden of Respiratory Syncytial Virus Disease

92

How I Treat Advanced Hepatocellular Carcinoma: Mastering Immunotherapy for Optimal Outcomes

93

Interdisciplinary Dialogue: A Cardiologist's Guide to Evidence-Based Obesity Care

94

Latest Advances in Breast Cancer: Essential Highlights From San Antonio 2024

95

Shaping the Future of Advanced Breast Cancer Care: A Deep Dive Into Novel Data and Emerging Therapies

96

The Great Debate: Is Seizure Freedom Always Achievable in Focal Epilepsy?

97

Advancing Precision Cancer Medicine: Unveiling the Future Frontier

98

Lack of Adherence to Basal Insulin: Are Once-Weekly Formulations the Solution?

99

COVID-19 and Oral Antivirals: How to Define an Eligible Patient

100

Thyroid Eye Disease: All You Need to Know

101

Charting New Horizons: Emerging Data and Novel Therapies in Relapsed/Refractory Follicular Lymphoma

102

HIV gp120 Importance Beyond Entry: Role in Immune Activation, Inflammation, and Comorbidities

103

Evolving Strategies for Metastatic Breast Cancer: A Deep Dive Into Recent Progress

104

Immunotherapy for Hepatocellular Carcinomas: Navigating the Dynamic Treatment Landscape

105

One Size Doesn't Fit All: A Practical Guide on How to Personalize Tacrolimus-Based Therapy in Transplant Recipients

106

HIV, Inflammation, and Clustered Comorbidities: Assessing Risks and Proactive Management

107

Brain Health and Brain Health Strategies in Epilepsy

108

Deciphering the Latest Clinical Data for EGFR-Mutated Advanced NSCLC: Unveiling Expert Insights

109

Amplify and Act: Case-Based Discussions With Heart Failure Experts

110

Lowering the Cardiovascular Burden With Novel Weight Loss Therapies: An Expert Digest From ESC

111

The Rise of the Machines: A Quickfire Exploration of Artificial Intelligence and Big Data in Oncology

112

Chikungunya Virus Vaccine: A New Addition to the Travel Vaccine Armamentarium

113

Undercover Partners: HIV, Immune Activation, and Inflammation

114

Patient-Centered Care in Newly Diagnosed Multiple Myeloma: Navigating Triplet and Quadruplet Therapy

115

Selecting Antiseizure Medications and Aiming for Seizure Freedom

116

Advances in Dermal Fillers: Hybrid Fillers and the Power of Regenerative Biostimulation

117

Treatment Goals and Targeted Therapies in Myasthenia Gravis

118

EHA 2024 Recap: Optimizing the Relapsed/Refractory CLL Treatment Pathway

119

Managing Diffuse Large B-Cell Lymphoma at First Relapse: Optimizing Patient-Centered Care

120

Incorporating Lipoprotein(a) Routinely Into Cardiovascular Risk Assessment: Why, What, Who, How, and When?

121

Immunotherapy for Early-Stage Resectable NSCLC: Optimizing Multidisciplinary Management Today

122

Exploring the Value of Delivering Lung Cancer Medicines in Different Ways: Optimizing the Patient Experience

123

Latest Advances in Breast Cancer Care: Highlights From Chicago 2024

124

Obesity Care: Improving Health Outcomes in Collaboration With the Patient

125

The Evolution of Incretins – A Revolution in Diabetes Management?

126

Dengue: A Leading Cause of Travel-Related Fever – Vaccinating Travelers to Endemic Regions

127

Unlocking the Power of Tumor-Agnostic Therapy: A Path to Personalized Cancer Care

128

Multiple Sclerosis Biosimilars in Europe: How to Communicate With Your Patient for Successful Implementation

129

A Deep Dive Into Long-Term Efficacy and Safety of LDL-Cholesterol Lowering: Modern Strategies for ASCVD

130

Antibody-Drug Conjugates in the Spotlight: Novel Strategies for Breast Cancer Management

131

Decoding Epilepsy Treatment Strategies: A Case-Based Exploration

132

Delivering Precision Oncology to Patients: From Principles to Practice

133

Chronic Inflammatory Demyelinating Polyneuropathy: How Insights From Disease Biology Inform Novel Therapies

134

Fine-Tuning Chronic Lymphocytic Leukemia Management: Optimising Bruton Tyrosine Kinase Inhibitor Use in Practice

135

Evolving Perspectives on HR-Positive Metastatic Breast Cancer: Current Understanding and New Insights

136

SGLT2 Inhibitors in the Post-Myocardial Infarction Population: Answering the Last Unanswered Question

137

Personalizing Care for Breast Cancer: The Precision Medicine Approach

138

A Roadmap to Relief: Managing Agitation in Dementia Associated With Alzheimer's Disease

139

Tailoring Bruton Tyrosine Kinase Inhibitor Strategies for CLL: Managing Today, Anticipating Tomorrow

140

How I Treat Alagille Syndrome

141

Novel Incretin-Based Dual/Triple Agonists: The Future in Diabetes Care?

142

Connecting the Clinical Clues of Alagille Syndrome

143

The Patient With Obesity in Primary Care: Novel Strategies for Sustained Weight Loss and Better Health Outcomes

144

The Physical Implications of Stigma in People Living With HIV

145

HER2-Positive Metastatic Colorectal Cancer: Unraveling Game-Changing Treatment Approaches

146

The Patient With High CV Risk and Obesity in Cardiology Care: Evidence-Based Strategies for Weight Loss and CV Risk Reduction

147

Unveiling the Bigger Picture of Alzheimer's Disease: From New Disease Mechanisms to Biomarkers

148

Lessons Learned in Long COVID: Impact on Patients and Progress in Management

149

Managing Menopause in Women Living With HIV

150

Development of Next-Generation Prophylactic Antibodies for COVID-19

151

Clinical Spotlight: Harnessing the Power of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

152

Transitioning Into Adult Care for Adolescents Living With HIV

153

Cardiovascular Event Reduction in People With Overweight or Obesity -- Evaluating the Evidence

154

Exploring the Ongoing Risk of Severe COVID-19 in At-Risk Populations

155

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio

156

Advanced NSCLC: Multidisciplinary and Patient Thoughts on How to Ease the Burden of Care

157

The Hidden Epidemic: Spotlight on the Unseen Impact of RSV on Adult Health

158

Next-Generation Monoclonal Antibodies for COVID-19: A Clinical Update

159

Influenza in Children: Expert Insights on the Current Burden of Disease

160

Optimizing Long-Term Management of Generalized Pustular Psoriasis: Are You Up to Date?

161

Complexities of Cardiometabolic Disease in People Living With HIV

162

New Therapies in Geographic Atrophy: First Experiences from US Clinical Practice

163

Preventing Respiratory Syncytial Virus in Infants: Understanding Evolving Epidemiology, Assessing Risk, and Protecting the Vulnerable

164

The Importance of Maintaining Respiratory Syncytial Virus Protection in At-Risk Infants via Passive Immunization

165

Raising the Bar: Optimizing Outcomes With IL-23/IL-17 Inhibitors in Spondyloarthritis

166

Testing and Timing for COVID-19 Therapies: Understanding Factors for Optimization

167

Evolving Paradigms of Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

168

Early-Stage Resectable NSCLC: A Shifting Landscape With Targeted Therapies and Immunotherapy

169

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Multidisciplinary Perspectives on Managing and Maximizing Care

170

Diabetes Dialogue: Can We Reduce the Disease Burden with Weekly Basal Insulin?

171

Understanding the Role of Biologics in Hidradenitis Suppurativa: A Journal Club Review of Recent Data and Clinical Impacts

172

The Evolving Treatment Landscape for Patients With Psoriatic Disease

173

Value of Influenza Vaccination in Children: Impact on Transmission and Burden in the Whole Population

174

Neurocognitive Disorders in People Living With HIV: Cause and Consequence

175

New Therapies for Neovascular AMD and DME: What Have We Learned?

176

Identifying Progressive Pulmonary Fibrosis on Imaging and Collaborating With the Multidisciplinary Team

177

Demystifying Drug-Drug Interactions for COVID-19 Antivirals

178

CD19-Targeting in Relapsed/Refractory DLBCL: Optimizing the Use of Noncellular Therapies

179

Clinical Context of the Consensus: A Review of the Latest Recommendations for Waldenström Macroglobulinemia

180

Dengue Vaccination in Endemic Populations: Implementation Strategies in Diverse Settings

181

When Hyperkalemia Impairs Optimal Treatment of HF and CKD: What New Guidelines Recommend

182

Epilepsy and Depression: Managing Common Situations

183

Neprilysin Inhibition: In Heart Failure and Beyond

184

What Are the Patients' Unmet Needs in C3 Glomerulopathy? Clinical Pearls on Current Management and Future Perspectives

185

Hot Topics in Breast Cancer Clinical Research: Challenges, Opportunities, and Implications for Practice

186

Optimizing Immunotherapy Combination Strategies for Metastatic NSCLC: From Evidence to Practice

187

Biosimilars 101: From Neurologists, for Neurologists

188

Diabetes Dialogue: Breaking Down Barriers to the Early Use of GLP-1 RAs in Primary Care

189

COVID-19 and Antivirals: Expert Evaluation of Data in High-Risk Patient Populations

190

New Lipid-Lowering Therapies in Atherosclerotic Cardiovascular Disease: Who, How, When, and for How Long?

191

Early-Onset Schizophrenia: Integrated Service Provision and Optimizing Care

192

Retinal Disease: An Update on Emerging Technologies

193

Generalized Pustular Psoriasis: What Do You Know About the Unmet Needs for Patients?

194

COVID-19 in the Current Era: Expert Insights on Oral Antivirals for Nonhospitalized Patients

195

The Simple Mathematics of Lipid-Lowering Therapies and Targets in ASCVD: What Every Healthcare Professional Needs to Know

196

Advances in the Management of Immunoglobulin G-Mediated Autoimmune Diseases

197

BTK Inhibitors for Chronic Lymphocytic Leukemia: Rapid-Fire Highlights From the Past Year

198

Managing Generalized Pustular Psoriasis: A Micro Learning Series

199

Sudden Unexpected Death in Epilepsy (SUDEP): The Essentials for Sensitive and Informed Conversations

200

Navigating the Changing Landscape in Myasthenia Gravis: An Expert Case-Based Discussion

201

Finding the Needle in the Haystack: Following the Journey of a Patient With C3G

202

Managing Early-Stage Resectable Non-Small Cell Lung Cancer: Through the Eyes of the Patient and the Care Team

203

Neonatal Fc Receptor in IgG-Mediated Autoimmune Disorders: Looking at a Common Denominator

204

Nutrients and Infant Neurodevelopment: Comparative Assessment on Impact of Individual Nutrients Over the Long Term

205

Latest Advances in Systemic Treatment for Breast Cancer: Evidence and Implications

206

Clinical Pearls: Getting Low-Density Lipoprotein-Cholesterol Levels to Target and Keeping Them There

207

Managing Adverse Events of Novel Antibody-Drug Conjugates in Breast Cancer

208

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

209

Epilepsy and Its Burden: The Voice of the Caregiver

210

Development of Heart Failure Following Myocardial Infarction: What Is the Unmet Need?

211

Impact of Nutritional Management for Cow's Milk Allergy: Can It Interrupt the Allergic March?

212

Long-Term Management of Reflux and Deprescribing PPI Therapy: Expert Perspectives

213

Dengue: Vaccinating Travelers to Endemic Regions

214

A Patient With Type 2 Diabetes and Chronic Kidney Disease in Clinical Practice

215

Demystifying the Science of New Anti-Seizure Medications and Application to Clinical Practice

216

Development of Heart Failure Following Myocardial Infarction: Why Risks Still Remain High

217

Expert Exchange: Clinical Implications of the Latest Advances in Metastatic Breast Cancer

218

Meeting the Experts and Taking Action in Heart Failure

219

Classification and Nomenclature of IC-MPGN and C3G: A Spectrum of Diseases or Distinct Entities?

220

Adherence to Lipid-Lowering Therapies: How Can We Tackle This Barrier Better?

221

Adherence to Lipid-Lowering Therapies: How Can We Tackle This Barrier Better?

222

A Patient Is Waiting for a Liver Transplant: What Can We Do Now and What Could We Have Done Better?

223

Reducing the Risks of Hyperkalemia in the Treatment of Heart Failure and Chronic Kidney Disease: What It Means for Management Teams

224

Dengue Prevention: Integrating Vaccination Into Comprehensive Control Strategies Across Populations

225

Early-Stage Resectable Non-Small Cell Lung Cancer: Sharing Patient Perspectives

226

Gaining Control With Early Combination Lipid-Lowering Therapy: Applying Learnings From the Queen's Gambit

227

Looking Forward to Thriving With HIV: Interventions to Improve and Maintain Health in People With HIV

228

Three Cardiovascular Risk Cases: Why and Who Should We Be Testing for Lp(a)

229

Well Begun Is Half Done: Why and How Do We Assess Activity of the Complement Pathway in the Clinic?

230

What's New in Diabetic Eye Disease Technologies

231

Biosimilars in Multiple Sclerosis: Entering a New Era of Biologic Therapy

232

Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Mediated Diseases

233

Global Perspectives on Anti-Vascular Endothelial Growth Factor: If, When, and How to Switch

234

Clinical Trials in Focus: Durability of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies

235

Safeguarding the CKD Patient With or Without Diabetes in Primary Care: Quick Questions, Rapid Replies

236

Optimizing Treatments in Advanced Systemic Mastocytosis With Associated Hematological Neoplasm

237

Diabetes Dialogue Part 2: Who Are Candidates for GLP-1 Receptor Agonist Therapy in Primary Care?

238

Challenging the Harmful Myths About ASCVD Management: The Experts Set the Record Straight

239

What Is the Expert Accord on Identifying and Protecting the Patient at Early Stage of CKD?

240

Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?

241

Pros and Cons of COVID-19 Vaccination in Children: Weighing the Evidence

242

The Road to Safety: Understanding the Common and Less Common Side Effects of COVID-19 and Other Vaccines

243

Recovering Immune Responses in Heavily Treatment-Experienced HIV-Positive Individuals

244

COVID-19 Immunization in Oncology and Stem Cell Transplant Settings: Experts Provide Practical Guidance

245

Chronic Kidney Disease – Looking Beyond Diabetes: Expert Interpretation of Latest Evidence From Kidney Outcome Trials

246

Dengue Immunization: Special Populations

247

Evolving Hesitancies and Objections to COVID-19 Booster Shots: Separating Facts From Fiction

248

Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding the Data and Their Implications

249

Early-Stage Resectable Non-Small Cell Lung Cancer: Navigating a Changing Treatment Landscape

250

Advanced Age-Related Macular Degeneration: How to Use Imaging to Screen and Monitor Patients

251

Insights and Understanding of the Impact of Inflammation in HIV-Positive Individuals

252

Ideal Dengue Vaccine Characteristics

253

Spotlight on Chronic Lymphocytic Leukemia: Exploring the Continued Evolution of Bruton Tyrosine Kinase Inhibitors for Our Patients

254

Where Are We Now in the Use of Interleukin-17 Inhibitors for Psoriatic Disease?

255

Improving the Diagnosis and Management of Cow's Milk Allergy

256

The Evolving Role of Digital Health Solutions for Patients With Diabetes on Insulin

257

EMPA-Kidney in Context: Expanding Our Understanding of Sodium-Glucose Cotransporter 2 Inhibition in Chronic Kidney Disease Management

258

What COVID-19 Vaccines Can and Cannot Do: Setting Realistic Goals in the Current Pandemic

259

The Latest Data on Lipid-Lowering Therapies for ASCVD and What it Means for Practicing Clinicians

260

COVID-19 Vaccine Clinical Compendium: Comparing Vaccines, Safety Status, and Future Perspectives

261

To Boost or Not to Boost: The Debate Continues

262

Advances in the Management of Complement-Mediated Kidney Diseases: A Year in Review

263

Geographic Atrophy: Expert Perspectives and Latest Data

264

Complex Clinical Cases for Specialists: Getting Patients to Target LDL-C Despite Barriers

265

Axial Spondyloarthritis: What Do You Know?

266

Raising the Bar: Implementing Treatment Goals in Clinical Practice for Spondyloarthritis

267

COVID-19 Boosters: Why Do We Need Them?

268

Why Lipoprotein (a) Matters Regarding Cardiovascular Risk, and What's New?

269

Understanding the Impact of Hidradenitis Suppurativa on Patients' Lives

270

Urticaria in Minutes: Key Topics in the Diagnosis, Assessment, and Management of Chronic Spontaneous Urticaria

271

RET Inhibitors for RET-Altered Non-Small Cell Lung Cancer: Identification, Treatment, and Practicalities

272

Solving the Puzzles for B-Cell Malignancies: Navigating the Place of BTK Inhibitors Today and Tomorrow

273

Latest Perspectives for Managing EGFR TKI-Refractory and Resistant Non-Small Cell Lung Cancer: Updates From the European Oncology Congress

274

Latest Perspectives for Managing EGFR TKI-Refractory and Resistant Non-Small Cell Lung Cancer: Updates From the European Oncology Congress

275

New Frontiers in Neutrophilic Dermatoses: Role of the IL-36 Pathway

276

A Case-Based Approach: Implementing Patient-Centered Care in Reflux Disease

277

Quizzing the Experts: Why Is Combination Therapy in Dyslipidemia Started Too Late, and Why Does It Matter?

278

Is Chronic Pain Avoidable? A 3-Tiered Approach to Prevent Chronicity – Assess/Manage/Communicate

279

Wilson Disease Yesterday, Today, and Tomorrow: Following a Patient's Journey

280

Tools to Get to LDL-C Target With Better Adherence: The Experts Share Experiences With New Therapies

281

COVID-19 Bivalent mRNA Vaccines: Covering Variants in the Transition to Endemicity

282

Diagnosis and Management of C3G: A Collaborative Effort Between Pathologists and Nephrologists

283

Obesity and CV Disease: Lowering CV Risk With Novel Weight Loss Strategies

284

Modernizing the Management of Heart Failure: Implementation Is Critical to Success

285

An Update on C3 Glomerulopathy: Understanding a Rare Complement-Mediated Kidney Disease

286

Not Just Dry Eye: Everyday Case Challenges

287

Clinical Pearls on the Management of Wilson Disease With Neurological Features

288

Management of Wilson Disease in the Gastroenterology Setting: Guidance on Current Clinical Strategies

289

Genetic Counselling for Leber Hereditary Optic Neuropathy Patients and Their Families

290

Getting Social About Constipation: Enhancing the Patient-Provider Dialogue

291

"Life Can Only Be Understood Backwards, But It Must Be Lived Forwards": Major Depressive Disorder Today and Tomorrow

292

We've Seen All the Data, But How Do We Now Treat Heart Failure: A Case-Based Approach

293

Dengue: A Burden Throughout the Life Course

294

Wilson Disease: A Challenging Diagnosis in the Neurology Setting

295

Wilson Disease: A Challenging Diagnosis in the Gastroenterology Setting

296

Tackling the Obesity Pandemic: The Central Role of the Primary Care Physician

297

Pediatric COVID-19 Vaccination: Expert Perspectives and Data Analysis

298

Challenges and Opportunities in Achieving Treat-to-Target in Psoriatic Arthritis

299

Driving Evidence-Based Treatment: The Role of the Thoracic Multidisciplinary Team in Early-Stage Lung Cancer

300

A Wolf in Sheep's Clothing: The Spectrum of Morbidity Due to Epstein-Barr Virus

301

Three's a Crowd: The Interaction Between RSV, Immune Responses, and Frailty

302

Quickfire Updates From Chicago: What's New for EGFR TKI Refractory and Resistant Non-Small Cell Lung Cancer?

303

Suspecting RSV in Older Adults: Clinical Signs and What to Seek

304

Wilson Disease: The Great Masquerader

305

Seizure Freedom for Patients with Focal Seizures: Can We Aim Higher?

306

Countdown to Knowledge of Novel Therapies for Generalized Pustular Psoriasis Flares

307

Complement in Rare Kidney Diseases: Different Diseases With a Common Denominator

308

My Challenges and Hopes for a Better Life With Major Depressive Disorder: The Voice of the Patient

309

Obesity Talk (Episode 2): Opportunities for the Use of Novel Anti-Obesity Medications in Clinical Practice?

310

Optimizing Outcomes With Biologic Therapies in Psoriatic Disease

311

Seismic Shifts in Heart Failure Management: How Sodium-Glucose Cotransporter-2 Inhibitors Are Changing How We Treat Our Patients

312

Targeting Angiopoietin-2: A New Approach in Retinal Diseases

313

How to Assess and Diagnose Food Allergies: Experts Discuss Best Practices and Recent Advancements

314

Advanced Age-Related Macular Degeneration: Assessment, Strategies, and New Therapies

315

Novel Therapies for NSCLC With EGFR Exon 20 Insertions: Practical Pearls for the Clinic

316

Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives

317

Clinical Perspectives on HER2-Targeted Antibody-Drug Conjugates: Treatment-Related Adverse Events

318

International Heart Failure Guidelines and the Latest Data: Out of Complexities, Simplicities Emerge With SGLT2 Inhibitors

319

Epilepsy and Depression: Early Recognition or Double Trouble?

320

Addressing the Challenge of Endocrine-Resistant Breast Cancer

321

Addressing the Challenge of HER2 Heterogeneity in Breast Cancer

322

Management Strategies to Optimize Outcomes in CKD-aP: A Case-Based Discussion

323

RSV: Omnipresent and Inescapable

324

The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI Resistance

325

The Implications of the Latest Data on SGLT2 Inhibitors in Heart Failure: A Unified Approach to Treatment?

326

Managing Psoriatic Disease With Biologic Therapies

327

Leber Hereditary Optic Neuropathy Gene Therapy – Who Should Be Treated and How?

328

Evolving Perspectives on How to Achieve Successful Outcomes in Crohn Disease

329

Immunopathogenesis of Hidradenitis Suppurativa

330

Treat Across the Heart Failure Spectrum or Dichotomize by Ejection Fraction Category? The Experts Debate

331

The Patient With Chronic Ocular Surface Pain: Taking the Next Step

332

Emerging Treatment Options for CKD-Associated Pruritis: Focus on Kappa Opioid Receptors

333

Novel Therapies for EGFR Exon 20 Insertions and ALK-Positive NSCLC: Developments and Implications

334

CAR T-Cell Therapy for R/R Multiple Myeloma: Sharing Expert Insights to Advance Outcomes

335

Geographic Atrophy: Complement Inhibitors and Implications for Clinical Practice

336

What's New in Biologic Therapies for Crohn Disease? An Update From Vienna

337

COVID-19 Vaccination in the Elderly: Experts Discuss Challenges and Current Recommendations

338

My Patient on Hemodialysis Has Itch Symptoms: What Should I Do?

339

Obesity Talk (Episode 1): How to Start a Conversation About Obesity With Your Patient?

340

Early Biologic Choice in Crohn Disease: Setting the Stage for Successful Outcomes

341

Clinical Controversies on NASH: Quick Questions – Rapid Replies

342

MEK Inhibitors for NF1-Related Plexiform Neurofibromas: An MDT Approach for Addressing Adverse Events, Adherence, and Patient Guidance

343

Herpes Zoster Immunization: Data Updates and Practice Essentials in the Current Landscape

344

Hepatosplenomegaly, Thrombocytopenia, and Bone Pain: What Next?

345

Immunoglobulin A Nephropathy: A Call to Action for Personalized Risk Assessment and Timely Management

346

The Beast With a Thousand Heads: Dispelling Myths and Misinformation Around COVID-19 Vaccines With Scientific Data

347

Unfolding the Future: How Will mRNA Technology Change the Landscape of Vaccination?

348

COVID-19 Vaccination of Immunocompromised Individuals: What Every Physician Should Know

349

Generalized Pustular Psoriasis: Understanding the Patient Experience

350

Major Depressive Disorder as a Psychiatric Emergency: Identifying Who Is at Highest Risk

351

Building Confidence in COVID-19 Vaccines: Why Are Millennials Hesitant?

352

Emerging From the Shadows: Expert Perspectives on the True Burden of RSV in Older Adults

353

Relapsed/Refractory Multiple Myeloma and CAR T-Cell Therapy: Navigating the Patient Journey

354

COVID-19 Vaccine Effectiveness in Variants of Concern: What Do We Currently Know?

355

The A to Z of Congenital Cytomegalovirus: Epidemiology, Burden of Disease, and Diagnosis

356

Neuro-Diabetes Crosstalk – Strategies for Stroke Prevention in Type 2 Diabetes

357

My Life With Uncontrolled Focal Seizures: The Voice of the Patient

358

Lifting the Load of Comorbidities in Women Living With HIV: Raising Awareness and Optimizing Care

359

COVID-19 Vaccination in Children: Experts Weigh In on the Evidence So Far

360

New Frontiers in Retina: Experts Discuss Novel Therapies & Technologies

361

Building Confidence in COVID-19 Vaccines: How to Talk to Your Younger Adults

362

Can You Recognize and Diagnose Generalized Pustular Psoriasis (GPP)?

363

Inertia In Major Depressive Disorder: A Journey of a Thousand Miles Begins With a Single Step

364

Re-Examining Multidrug Resistance in Heavily Pretreated PLWHIV With Few Antiretroviral Therapy Options

365

Fresh Perspectives on Geographic Atrophy: New Drugs and Latest Data

366

Milestones in COVID-19 mRNA Vaccine Development: How Did We Develop It so Quickly?

367

The Evolution in Systemic Breast Cancer Therapies: A Deeper Dive Into Recent Data

368

Deconstructing COVID-19 Vaccine Hesitancy: Providing Tailored Solutions Across the Spectrum

369

Immunotherapies in Relapsed/Refractory Multiple Myeloma: 2021 Round-Up and a Look Into the Future

370

The COVID-19 mRNA Vaccines: How Do They Work?

371

Screening for Nonalcoholic Steatohepatitis in the Patient With Metabolic Disorders

372

Evolving Best Practices for Managing AL Amyloidosis: Sharing Perspectives

373

Throughout a Lifetime: The Intersection of HIV and Biological Considerations in Women Living With HIV

374

Evolution or Revolution in HFrEF: What Now for Our Patients?

375

Early-Onset Schizophrenia in a New Light: A Patient's Testimony

376

Beyond Post-Herpetic Neuralgia: Awareness of Other Complications Associated with Herpes Zoster

377

Beyond Clinical Trials: What Does Real-World Evidence Tell Us About COVID-19 mRNA Vaccine Effectiveness and Safety?

378

To Boost or Not to Boost: What Does the Evidence Tell Us?

379

Recognizing the Risk of Herpes Zoster in Older Adults With Comorbidities

380

Failure to Recover CD4 in People Living With HIV: Clarifying the Causes and Related Consequences

381

Stepping Stones to Long-Term Obesity Management

382

Improving on the Past: Using Next-Generation BTK Inhibitors Effectively in B-Cell Malignancies

383

News on NASH – Selected Highlights from The Liver Meeting 2021

384

SGLT2 Inhibitors and Other Classes of Therapies in HFpEF: Examining The Totality of Clinical Data

385

Reviewing Outcomes for HFpEF With SGLT2 Inhibitors: A Data Deep Dive

386

Dengue: Strategies to Limit Human Exposure to Disease-Carrying Mosquitos

387

New Treatment Approaches for Geographic Atrophy: Focus on the Complement Cascade

388

Novel Dual GIP/GLP-1 Receptor Agonists: The Future Standard of Diabetes Care?

389

Examining the Latest European HFrEF Guidelines: Putting the Patient at the Center of Management

390

Sorting Out Sore Throats: Role of Nonsteroidal Anti-Inflammatory Lozenges

391

Diabetes Dialogue: Incretin Therapy According to Guidelines

392

Breast Cancer in 2021: Where Do We Stand, and What Is Yet to Come?

393

Updates in Chronic Spontaneous Urticaria From EADV: Experts Highlight the Latest Advances

394

Emerging Science Across the Spectrum of Breast Cancer: Latest Perspectives

395

HFrEF Guideline Recommendations in Practice: Living Life Forward

396

My Patient on Hemodialysis Has Itch Symptoms: How Concerned Should I Be?

397

HIV and Inflammation: Raising Awareness of the Impact of Inflammation on People Living With HIV

398

Walking Through the Major Changes in Heart Failure: Definitions, Guidelines, and Impact of Management

399

Fundamental Facts About Glucagon-Like Peptide-1 Receptor Agonists for the Diabetologist – Quick Questions / Rapid Replies

400

B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal

401

Optimizing the Nutritional Care of Preterm Infants

402

Updated Guidelines for Heart Failure With Reduced Ejection Fraction: Squinting Through the Fog

403

Zooming in on Cardiovascular Risk Control With Glucagon-Like Peptide-1 Receptor Agonists in Diabetes

404

Optimizing Outcomes in Diabetic Macular Edema: Why Fluid Matters

405

Can You Recognize and Diagnose CKD-aP?

406

Managing Cardiometabolic & COVID-19 Risks in Diabetes – A Vital News Bulletin for the Cardiologist

407

Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape

408

Neurodevelopmental Outcomes and Nutritional Strategies in Infants

409

Emerging Systemic Treatment Options Across the Spectrum of Breast Cancer Therapy

410

Understanding Geographic Atrophy: Disease Facts, Pathophysiology, Diagnosis, and Monitoring

411

Vitreoretinal Surgery Considerations for Novel Drug Technologies

412

Managing the Patient With DME: What's on the Horizon?

413

Mosquito-Borne Viral Diseases: Advice for Travelers to Endemic Areas

414

The Paramount Principles of Incretin Therapy: A Formula for Success in Primary Care

415

Why Should We Test for Lipoprotein(a)? The Experts Discuss

416

The Foundations of Immunization: What, Who, When and Why?

417

Changing Practice in Advanced/Metastatic Cholangiocarcinoma: What Clinicians Need to Know

418

From Genes to Cardiovascular Events: What All Physicians Need to Know About Lp(a)

419

Integrating Novel Therapies in the Management of Severe Asthma: Experts Discuss Challenging Cases

420

COPD: ICS Pros and Cons in Primary Care

421

Evolving Understanding on COVID-19 Vaccines and SARS-CoV-2 Variants

422

Essential Facts About Dual Incretin Receptor Agonists – Quick Questions, Rapid Replies

423

Succeeding Where No Other Therapy Has: SGLT2 Inhibition in HFpEF

424

Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis

425

Implementing New Lipid-Lowering Therapies Into Clinical Practice: 10 Frequently Asked Questions

426

Evolving Care Pathways in the Management of CRSwNP: Role of Biologics

427

Knowing Is Not Enough, We Must Apply: SGLT2 Inhibitors as Foundational Therapy for HFrEF

428

Vaccine Adjuvants: Levelling the Playing Field for Older Adults

429

MRD and FISH Testing in Patients With Multiple Myeloma: When and Why?

430

MRD and FISH Testing in Patients With Multiple Myeloma: When and Why?

431

nAMD: Poor Response -- When to Switch Therapies?

432

Implications of Immunosenescence for Immunization of Older Adults

433

Realizing the Opportunity of Molecularly Guided Therapy: How Do We Accelerate the Revolution?

434

siRNA Therapies in Dyslipidemia: A Clinical Primer

435

Lp(a) and Cardiovascular Risk: The New Kid on the Block

436

Treating Fever in Children: Calming "Fever Phobia" With Appropriate Antipyretic Therapy Guidance

437

COVID-19 Vaccines: The Beginning of the End?

438

The International Liver Conference – New Prospects for Dealing With NASH

439

Best Practices in the Management of Reflux Disease: Experts Discuss Patient Cases

440

Newly Approved Lipid-Lowering Therapies: The Top 5 Things to Know

441

Novel Immunotherapies in Relapsed/Refractory Multiple Myeloma: What Does the Future Hold?

442

Tailoring Management Strategies for My Patients With MS

443

Combination Therapy Choices in COPD -- State of the Art

444

Opportunities and Challenges in Early Breast Cancer: Do PARP Inhibitors Have a Role?

445

Advances in Chronic Lymphocytic Leukemia: New Data in Clinical Context

446

Dengue: Not Just 1 Virus, Not Just 1 Infection

447

Will New Treatments Transform Patient Care in nAMD and DME?

448

Taking the Next Step in Tackling Chronic Obesity: Insights From ECO 2021

449

Preventing HF After MI: What the Latest Data Tell Us

450

Intraocular Inflammation After Anti-VEGF Therapy: Latest Data and Guidance

451

Optimizing Access to Monoclonal Antibodies for COVID-19 Infection: The Global Perspective

452

My Patient's Cholesterol Is Still High Despite Treatment...Help!

453

What Is New in Biologic Therapy for Psoriasis: Updates From AAD

454

Putting International HF Treatment Pathways Into Practice: Willing Is Not Enough, We Must Do

455

Unfolding the Future of Chronic Spontaneous Urticaria: Emerging Data With Novel Therapies

456

Case Presentations in Severe Dengue: Contemporary Approaches to Clinical Management

457

The International Liver Conference – Ahead: NASH in Focus

458

The Role of SGLT2 Inhibitors in HFrEF Care: What Do the Latest Clinical Practice Documents Say?

459

New Molecularly Guided Therapies in Advanced/Metastatic Cholangiocarcinoma: What You Need to Know

460

Treating MS Early: Who, How, and When?

461

Bispecific Antibodies: The Case for Non-BCMA Targets

462

Tackling Adherence in Dyslipidemia: Concrete Actions for Better Outcomes

463

SARS-CoV-2 Vaccine Candidates: Expertise and Updates

464

Practical Strategies to Overcome Poor Vaccine Uptake During the COVID-19 Pandemic

465

COVID-19: The Path to Immunity

466

Optimal Implementation of the COVID-19 Vaccine: Best Practice and Strategies for Success

467

Beyond Clinical Trials: Treating nAMD in Clinical Practice

468

Molecularly Guided Therapy in Oncology Practice: The Evolving State of the Art

469

ENDO 2021 – New Directions With Weight Loss Concepts of the Future

470

Taking Control of Chronic Spontaneous Urticaria: A Tale of Two Perspectives

471

Advances in Oncogene-Driven Metastatic NSCLC: Focusing on EFGR Exon 20 Insertions and ALK-Positive NSCLC

472

HFpEF Is Arguably the Greatest Unmet Need in Cardiology: The Potential Role of SGLT2 Inhibitors

473

Patient Engagement in MS: What Does This Mean and What Does It Look Like?

474

Neuro-Ophthalmology: What You Need to Know About LHON

475

The Science of MS and Role of S1P Receptor Modulators

476

Emerging Therapies for Chronic Spontaneous Urticaria: Understanding How They Work

477

Molecular Testing – Transplant and Treatment Strategies in AML

478

New Approaches to Ocular Surface Pain

479

Defining NASH As a Metabolic Disease: Can We Afford to Ignore It?

480

Exploring New Targets in Generalized Pustular Psoriasis

481

Challenges and Unmet Needs in Food Allergy: How Big Is the Problem?

482

Fresh Perspective for Patients With nAMD and DME: New Therapies on the Horizon

483

Multiple Sclerosis Education Blitz: Interpreting Recent Advances in B-Cell-Targeted Therapies

484

People Living With HIV: Stifled by Stigma and Impact on Health Outcomes

485

PARP Inhibitor Maintenance in Newly Diagnosed Ovarian Cancer: Key Questions, Answers, and Insights

486

CKD-Associated Pruritus: Impact on Patient Quality of Life

487

The 2021 Heart Failure Treatment Pathway Revolution: What Every Clinician Needs to Know!

488

Dengue Diagnosis: Unique Challenges in a Time of Pandemic

489

Initiating COPD Therapy in Primary Care

490

Development of HF After MI: The Science of Why This Occurs

491

When Interstitial Lung Disease Encounters COVID-19: Clinical Considerations

492

Emerging Treatment Pathways for HFrEF Patients: What Does the Evidence Say?

493

Multidisciplinary Management of Connective Tissue Disease-Associated Interstitial Lung Diseases

494

Current and Emerging Therapies for CKD-Associated Pruritus

495

Update on IL-17 Inhibitors in the Management of Psoriasis

496

HER2 Testing for the Pathologist: Is Your Clinic Up to Date With the Latest Developments?

497

My Life With MS: A Patient Testimony

498

CAR T-Cell Therapy in Real Practice: Optimizing Referral and Treatment of Patients With NHL

499

Latest Data and Perspectives on NASH From the Liver Meeting

500

SGLT2 Inhibitors in Chronic HF Patients: Safety in Clinical Practice

501

The Changing Landscape for HER2+ Advanced Breast Cancer: Clinical Experience With Anti-HER2 Agents

502

Protecting the Diabetic Kidney With Glucose-Lowering Drugs: Essential News for the Nephrologist

503

SGLT2 Inhibitor Data Review: What's New in HFrEF?

504

Managing Patients With Chronic HF Using SGLT2 Inhibitors: Exploring Practical Considerations

505

Understanding the Challenges of Immunosuppression in Kidney Transplant Patients of Childbearing Age

506

Diabetes Insights: The Impact of GLP-1 RAs on Renal Outcomes

507

MS and COVID-19: Rounding Up the Year's Experiences

508

Current and Emerging Therapies for CKD-Associated Pruritus

509

Multifocal Motor Neuropathy: Identifying and Managing a Debilitating Lower Motor Neuron Syndrome

510

An Image Is Worth a Thousand Words: Diagnostic Tips and Tricks in Identifying Fibrotic Lung Disease

511

Transforming Weight Loss Management for Chronic Obesity

512

Combination Therapy in COPD: What Are the Choices?

513

Evolving Paradigms in Myeloma Maintenance

514

Cardiometabolic Risk Control in Diabetes: Latest Insights and Recommendations

515

Adjuvant EGFR TKI Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Current and Future Perspectives

516

New Paradigms for Progressive Fibrosing Interstitial Lung Diseases

517

Exploring New Targets in the IL-23/IL-17 Pathway for Psoriasis

518

The Present and Future of Next-Generation Insulins

519

A Call to Action for Improving Disease Control in Chronic Spontaneous Urticaria: From Guidelines to Clinical Practice

520

SGLT2 Inhibitor Treatment for HFrEF: Demonstrating Safety Beyond the Heart

521

CAR T-Cell Therapy in Lymphoma: Preparation, Communication, and Aftercare

522

IVT Anti-VEGF Therapy: Practical Strategies to Protect Vision and Mitigate Risks

523

Addressing Key Challenges and Unmet Needs in GPP Management

524

A Case-Based Approach to Early Intervention in Schizophrenia: Optimizing Service Provision

525

Cardiometabolic Risk Management With Glucose-Lowering Drugs: Essential News for the Cardiologist

526

Understanding the Immunopathogenesis of CKD-Associated Pruritus

527

Catching and Managing Progressive Fibrosing Interstitial Lung Disease Progression Earlier

528

Latest Insights into CV Risk Reduction with GLP-1 RAs

529

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapy

530

What Are the Effects of SGLT2 Inhibitors In Patients With HFrEF?

531

Optimizing Bronchodilator Therapy in COPD

532

Sin fronteras: perspectivas sobre la optimización del diagnóstico precoz de las infecciones respiratorias y de la meningitis y la encefalitis

533

CD38 Antibodies in Multiple Myeloma: What Next?

534

A Comprehensive Approach to Diagnosis and Treating Patients With Psoriasis and Back Pain

535

Behind the Scenes: Evaluating the Safety of the Expanding Hemophilia A Therapy Armamentarium

536

Clinical Benefits of Fixed-Dose ICS/LABA/LAMA Combination Inhalers in the Management of Asthma

537

Emerging CART-Cell Therapies in Multiple Myeloma: The Evidence and Implications

538

Highlighting New Data in Multiple Myeloma

539

Diabetology and Cardiology in Dialogue -- What is State-of-the-Art for Best Diabetes Care?

540

Risk Assessment in Dyslipidemia For Specialists: An Expert Walkthrough

541

Strategies for Enhancing Patient Adherence to Asthma Therapy

542

Generalized Pustular Psoriasis: What Do You Know?

543

Hyperkalemia and Dialysis: Challenges and Solutions for Improving Management

544

Best Practice Treatment of Relapsed/Refractory Indolent NHL: Case Insights

545

What Have We Learned About Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic?

546

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

547

CAR T Cells and Hypogammaglobulinemia: What Do We Know and How Do We Manage Patients?

548

CLL and MRD Negativity in Practice: Patients and Practicalities

549

Managing Asthma During the COVID-19 Pandemic: Experts Provide Guidance

550

The Journey Toward Personalized Care in COPD: Where Are We Now?

551

Prevention of Microvascular Complications in Diabetes: Where Do We Stand?

552

Macrovascular Complications in Diabetes: Most Recent Data and Insights

553

The Patient Journey With Dyslipidemia: A Patient's Perspective

554

Principles and Best Practices to Prevent Congenital CMV

555

A Digest of Latest Clinical Data With GLP-1 Receptor Agonists

556

Next-generation Insulins -- What's New?

557

Taking Individualized Neurology Care to the Next Level: The Role of Artificial Intelligence

558

Overcoming Challenges in Ophthalmology: Using Artificial Intelligence to Personalize Care

559

Managing COPD During the COVID-19 Pandemic: Experts Provide Guidance

560

Dyslipidemia Guidelines: Key Takeaways for the Primary Care Physician

561

Familial Hypercholesterolemia: What Every Primary Care Physician Needs to Know

562

Exploring Analgesic Options for Dental Pain

563

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): What Clinicians Need to Know About This Condition

564

Hypogammaglobulinemia in Patients With Hematologic Malignancies: Practical Considerations for Diagnosis and Management

565

The COVID-19 Pandemic: What Every Clinician Needs to Know, Now

566

Head-to-Head Studies in PsA: Understanding the Outcomes

567

Recent Developments in the Management of Patients with Moderate to Severe Asthma

568

GLP-1 Receptor Agonists for Primary Care: What's New? – Quick Questions – Immediate Insights

569

Managing Patients With Inflammatory Diseases During the COVID-19 Pandemic

570

Unmet Needs in Familial Hypercholesterolemia Management Today

571

Recognizing Familial Hypercholesterolemia and What to Do Next

572

Managing Patients With Multiple Myeloma in the COVID-19 Environment

573

COVID-19: Respiratory and Cardiovascular Considerations

574

Managing Patients With SLE During the COVID-19 Pandemic

575

The Molecular Tumor Board in Action: Understanding the Role and Benefit Through Real-World Case Studies

576

Diabetology and Cardiology in Dialogue -- What is State-of-the-Art for Best Diabetes Care?

577

COVID-19 Management: Practice Essentials and Answers From the Experts

578

Optimizing Treatment in Patients With Moderate to Severe Psoriasis

579

Evaluation of Biologic Therapies in Psoriasis: What Is the Evidence Beyond Clinical Trials?

580

Time to Reassess Biomarkers in Multiple Myeloma?

581

COVID-19 Pandemic: Further Implications for Diabetes Care

582

Early Intervention in COPD: Are 2 Bronchodilators Better Than 1?

583

COVID-19 and Mental Health: Taking Positive Action in This New Environment

584

COVID-19 and Comorbidities: Unhappy Bedfellows

585

COVID-19 Pandemic: The Implications for Diabetes Care

586

The Evolution of Knowledge on COVID-19 and Multiple Sclerosis

587

Moving Towards Routine Use of Comprehensive Genomic Profiling Across Oncology: From Clinical Rationale to Practical Application

588

What You Need to Know About CAR T-Cell Therapy in Multiple Myeloma: A Deep Dive

589

What You Need to Know About CAR T-Cell Therapy in NHL: A Deep Dive

590

What We Currently Know About COVID-19 and MS

591

The AxSpA Spectrum of Diseases: How to Diagnose and Manage Patients in Clinical Practice?

592

Patients With ND AML Unfit for Intensive Chemotherapy: Tailoring Treatment

593

COPD: Patient Selection Based on GOLD Guidance and Response to Therapy

594

CAR T-Cell Therapy in Non-Hodgkin Lymphoma and Multiple Myeloma: A Clinical Update

595

Implementing Multiple Myeloma Clinical Trial Data in Real-World Practice

596

Idiopathic Pulmonary Fibrosis: The Right Treatments at the Right Time

597

Approaching a New Era in the Management of Progressive Fibrosing ILDs

598

How Can We Meet the Treatment Needs of Patients With Systemic Sclerosis-Interstitial Lung Disease?

599

Working Together to Diagnose Idiopathic Pulmonary Fibrosis

600

The Progressive Phenotype of Non-IPF ILD: Clinical Relevance and Identification